The short version of salt form fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
In addition, San Martín came to be accused of falling into a serious anti-Peruvian hypocrisy with the monarchical project of the Protectorate of San Martín, by preferring the coming of European princes (betraying several nationalist Peruvians), leaving aside the already existing and millennial institutions national monarchists in Peru to imitate the parliamentary constitutionalism of the English and French in the restoration (being accused of being Anglophile and Frenchified by Peruvian Hispanicism), as well as having little or no consideration for monarchical proposals that represented the interests of the indigenous nobility (being accused of Criollo elitist by the Peruvian indigenism). For example, the case of the indigenous nobility of the Cajamarca region, which, after obtaining knowledge of the sworn independence on January 8, 1821, by Torre Tagle (despite the exclusion of indigenous representatives from the Cabildo de Naturales and famous curacas in rural populations, such as Manuel Anselmo Carhuaguatay), he tried to introduce himself and propose that the form of government of the new Peruvian state should correspond to a descendant of Atahualpa who lived in the town, the most notorious being Don Manuel Soto Astopilco (main cacique of the Seven Huarangas of the province), in addition to suggesting the rebirth of the State of Tahuantinsuyo and its right to the crown. No news was recorded that he tried to invoke possible links with the distant and exhausted Incas of Cusco (mostly more favorable to the Royal Army of Peru).
== History == George Gulliver in 1841 drew pictures of platelets using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister. This microscope improved resolution sufficiently to make it possible to see platelets for the first time. William Addison in 1842 drew pictures of a platelet-fibrin clot. Lionel Beale in 1864 was the first to publish a drawing showing platelets. Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material. Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo. He named Schultze's spherules (It.) piastrine: little plates. Bizzozero possibly proposed the name Blutplattchen. William Osler observed platelets and, in published lectures in 1886, called them a third corpuscle and a blood plaque; and described them as "a colorless protoplasmic disc". James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication, changing to platelets in his 1910 publication.
He told Gorbachev, "We understand the need for assurances to the countries in the East. If we maintain a presence in a Germany that is a part of NATO, there would be no extension of NATO's jurisdiction for forces of NATO one inch to the East." The following day, meeting Kohl in Moscow, Gorbachev voiced no fundamental objection to unification, provided Soviet concerns over borders, alliance structure, and the GDR's economic ties received due consideration; both German states, he observed, had absorbed the lessons of their shared history. Meanwhile, National Security Council staffer, Condoleezza Rice, plainly stated that the Soviets were in no position to resist German reunification. Reassurances from U.S. officials and Germany's financial aid payments sufficiently placated the Soviets at the time. The final settlement, worked out between Kohl and Gorbachev at Arkhyz in July 1990 and finalized that September, traded Soviet military withdrawal from East Germany for 12 billion deutschmarks plus an interest-free credit of another 3 billion—leading Deputy Secretary of Defense Robert Gates to remark that the Soviet Union had, quite literally, been "bribed out" of Europe. The concession provoked fury among Gorbachev's own advisers, such as Valentin Falin, who warned in a memorandum that NATO membership for a united Germany would "solidify the separation of European security" and give "impetus to NATO's advance to the Soviet Union's borders along the entire frontline."
=== DHS partial shutdown starting February 14, 2026 === A partial shutdown of the Department of Homeland Security began on Saturday, February 14, 2026. Most of the government employees affected will be expected to keep working, but their paychecks may be delayed depending on the length of the shutdown. This affects the Transportation Security Administration (TSA), Federal Emergency Management Agency (FEMA), Cybersecurity and Infrastructure Security Agency (CISA), U.S. Secret Service, U.S. Coast Guard, and Immigration and Customs Enforcement (ICE). The disagreement between Republicans and Democrats in Congress pertains most recently to the situation in Minneapolis, Minnesota and more generally to immigration enforcement policies and actions by the Trump administration. Democrats are asking for judicial warrants before agents can enter private property, a ban on ICE agents wearing face masks, the mandatory use of body cams, and new laws for use-of-force standards. In fact, both President Trump and Homeland Security Secretary Kristi Noem have spoken in favor of body cams starting in Minneapolis and going nationwide as funding becomes available.
Sources: en.wikipedia.org
=== Transferring a hydride and releasing a proton === Sometimes a dehydrogenase catalyzed reaction will look like this: AH + B+ ↔ A+ + BH when a hydride is transferred. A represents the substrate that will be oxidized, while B is the hydride acceptor. Note how when the hydride is transferred from A to B, the A has taken on a positive charge; this is because the enzyme has taken two electrons from the substrate in order to reduce the acceptor to BH. The result of a dehydrogenase catalyzed reaction is not always the acquisition of a positive charge. Sometimes the substrate loses a proton. This may leave free electrons on the substrate that move into a double bond. This happens frequently when an alcohol is the substrate; when the proton on the oxygen leaves, the free electrons on the oxygen will be used to create a double bond, as seen in the oxidation of ethanol to acetaldehyde carried out by alcohol dehydrogenase in the image on the right. Another possibility is that a water molecule will enter the reaction, contributing a hydroxide ion to the substrate and a proton to the environment. The net result on the substrate is the addition of one oxygen atom. This is seen for example in the oxidation of acetaldehyde to acetic acid by acetaldehyde dehydrogenase, a step in the metabolism of ethanol and in the production of vinegar.
=== Thermotherapy === For pain management, heat can be used to relieve stiffness, and cold can relieve muscle spasms and pain. The use of ice or cold packs may be beneficial; however, further research is needed. A 2003 Cochrane review of seven studies between 1969 and 1999 found ice massage to be of significant benefit in improving range of motion and function, though not necessarily relief of pain. Cold packs could decrease swelling, but hot packs did not affect swelling. Heat therapy could increase circulation, thereby reducing pain and stiffness, but with the risk of inflammation and edema. Another review found no evidence of benefit from placing hot packs on joints.
== Contrast with subduction zone island arcs == Hotspot volcanoes are considered to have a fundamentally different origin from island arc volcanoes. The latter form over subduction zones, at converging plate boundaries. When one oceanic plate meets another, the denser plate is forced downward into a deep ocean trench. This plate, as it is subducted, releases water into the base of the over-riding plate, and this water mixes with the rock, thus changing its composition causing some rock to melt and rise. It is this that fuels a chain of volcanoes, such as the Aleutian Islands, near Alaska.
Its historic outcome was an unprecedented call for a halt in research until it could be regulated in such a way that the public need not be anxious, and it led to a 16-month moratorium until National Institutes of Health (NIH) guidelines were established. Joshua Lederberg was the leading exception in emphasizing, as he had for years, the potential benefits. At Asilomar, in an atmosphere favoring control and regulation, he circulated a paper countering the pessimism and fears of misuses with the benefits conferred by successful use. He described "an early chance for a technology of untold importance for diagnostic and therapeutic medicine: the ready production of an unlimited variety of human proteins. Analogous applications may be foreseen in fermentation process for cheaply manufacturing essential nutrients, and in the improvement of microbes for the production of antibiotics and of special industrial chemicals." In June 1976, the 16-month moratorium on research expired with the Director's Advisory Committee (DAC) publication of the NIH guidelines of good practice. They defined the risks of certain kinds of experiments and the appropriate physical conditions for their pursuit, as well as a list of things too dangerous to perform at all. Moreover, modified organisms were not to be tested outside the confines of a laboratory or allowed into the environment.
Alfred Ellis Wilhelmi (1910–1994) was an American endocrinologist recognized for contributing to the understanding of anterior pituitary hormones. Born in Lakewood, Ohio, Wilhelmi attended Cleveland public schools. Wilhelmi earned a B.S. degree in premedical sciences from Western Reserve University in 1933. He then attended Oxford University as a Rhodes Scholar, where he obtained a B.A. in 1933 and Ph.D. in animal physiology in 1937. He then joined Yale University's Biochemistry Department, rising to the position of Professor in 1950. Wilhelmi chaired the Department of Biochemistry at Emory University School of Medicine from 1950 to 1977. In 1960, he was named Charles Howard Candler Professor of Biochemistry. In 1979, he received Emory's Thomas Jefferson award for service to the university and community. Wilhelmi also was President of the Endocrine Society from 1968 to 1969. During his career, he published over 80 articles in scientific journals.
Sources: en.wikipedia.org
The SC was decommissioned in 1990, after having been in operation for more than three decades. As a consequence, the collaboration decided to relocate the ISOLDE facility to the Proton Synchrotron, and place the targets in an external beam from its 1 GeV booster. The construction of the new ISOLDE experimental hall started about three months prior to the decommissioning of the SC. With the relocation also came several upgrades. The most notable being the installation of two new magnetic dipole mass separators. One general-purpose separator with one bending magnet and the other one is a high-resolution separator with two bending magnets. The latter one is a reconstructed version of the ISOLDE 3. The first experiment at the new facility, known as ISOLDE PSB, was performed on 26 June 1992. In May 1995, two industrial robots were installed in the facility to handle the targets and ion sources units without human intervention.
=== Discovery === Two groups claimed discovery of the element. Evidence of bohrium was first reported in 1976 by a Soviet research team led by Yuri Oganessian, in which targets of bismuth-209 and lead-208 were bombarded with accelerated nuclei of chromium-54 and manganese-55, respectively. Two activities, one with a half-life of one to two milliseconds, and the other with an approximately five-second half-life, were seen. Since the ratio of the intensities of these two activities was constant throughout the experiment, it was proposed that the first was from the isotope bohrium-261 and that the second was from its daughter dubnium-257. Later, the dubnium isotope was corrected to dubnium-258, which indeed has a five-second half-life (dubnium-257 has a one-second half-life); however, the half-life observed for its parent is much shorter than the half-lives later observed in the definitive discovery of bohrium at Darmstadt in 1981. The IUPAC/IUPAP Transfermium Working Group (TWG) concluded that while dubnium-258 was probably seen in this experiment, the evidence for the production of its parent bohrium-262 was not convincing enough. In 1981, a German research team led by Peter Armbruster and Gottfried Münzenberg at the GSI Helmholtz Centre for Heavy Ion Research (GSI Helmholtzzentrum für Schwerionenforschung) in Darmstadt bombarded a target of bismuth-209 with accelerated nuclei of chromium-54 to produce 5 atoms of the isotope bohrium-262:
=== Phase 2 === AD-036 – undefined mechanism of action [6] Atomoxetine/mineralocorticoid receptor antagonist (atomoxetine/antimineralocorticoid; AD-113) – combination of atomoxetine (norepinephrine reuptake inhibitor) and a mineralocorticoid receptor antagonist [7] Atomoxetine/trazodone (trazodone/atomoxetine; AD-504) – combination of atomoxetine (norepinephrine reuptake inhibitor) and trazodone (various actions/hypnotic) [8] BAY-2586116 – potassium channel blocker [9] CX-1739 – ampakine (AMPA receptor positive allosteric modulator) [10] Dronabinol low-dose (tetrahydrocannabinol; THC; PP-001) – cannabinoid CB1 and CB2 receptor agonist [11] Dronabinol/palmidrol (SCI-110; THX-OSA01; THX-RS01; THX-110; THX-TS01; THC/PEA) – combination of dronabinol (THC; cannabinoid receptor agonist) and palmidrol (palmitoylethanolamine (PEA); various actions) [12] Lorundrostat (MLS-101; MT-4129) – aldosterone synthase (CYP11B2) inhibitor [13] Phentermine/topiramate (Qnexa; Qsiva; Qsymia; topiramate/phentermine; VI-0521) – combination of phentermine (norepinephrine releasing agent) and topiramate (various actions) [14] Research programme: Sleep disordered breathing therapeutics - Shinogi-Apnimed Sleep Science – undefined mechanisms of action [15] SASS-001 – purinergic P2X3 receptor antagonist [16] Sivopixant (S-600918) – purinergic P2X3 receptor antagonist [17] Sulthiame (SASS-002; sulthiame; Sultia; sultiame) – carbonic anhydrase inhibitor [18] [19] Trazodone/viloxazine (AD-816; viloxazine/trazodone) – combination of trazodone (various actions/hypnotic) and viloxazine (norepinephrine reuptake inhibitor) [20]
As of 2024, the United Nations reports Ghana has a population of 34,581,288. As of 2018, around 29% of the population is under the age of 15, while persons aged 15–64 make up 57.8% of the population. The 2010 census reported that the largest ethnic groups are the Akan (47.3%), the Mole-Dagbani (18.5%), the Ewe (13.9%), the Ga-Dangme (7.4%), the Gurma (5.7%) and the Guan (3.7%). As of 2024, the United Nations reports the median age of Ghanaian citizens is 21 years old. Ghana contributes 0.42% to the total world population. With legal immigration of skilled workers who possess Ghana Cards, there is an increasing population of Chinese, Malaysian, Indian, Middle Eastern, American and European nationals and their descendants born in Ghana. In 2010, the Ghana Immigration Service reported economic migrants and undocumented immigrants inhabiting Ghana: 14.6% (or 3.1 million) of Ghana's 2010 population (mostly Nigerians, Burkinabe citizens, Togolese citizens, and Malian citizens). In 1969, under the "Ghana Aliens Compliance Order" enacted by then Prime Minister Kofi Abrefa Busia, the Border Guard Unit deported more than 3,000,000 aliens and undocumented immigrants in three months as they made up 20% of the population at the time. In 2013, there was a mass deportation of undocumented miners, more than 4,000 of whom were Chinese nationals.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.